Atypical muscarinic allosteric modulation: Cooperativity between modulators and their atypical binding topology in muscarinic M2 and M 2/M5 chimeric receptors

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1597-1610

  Tränkle, Christian ^a   Dittmann, Andreas ^a   Schulz, Uwe ^a   Weyand, Oliver ^a   Buller, Stefan ^a   Jöhren, Kirstin ^b   Heller, Eberhard ^c   Birdsall, Nigel J M ^d   Holzgrabe, Ulrike ^c   Ellis, John ^e   Höltje, Hans Dieter ^b   Mohr, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' BIS[(2,6 DICHLOROBENZYLOXYIMINO)METHYL] 1,1' PROPANE 1,3 DIYLBISPYRIDINIUM DIBROMIDE; ATYPICAL ANTIPSYCHOTIC AGENT; HEXAMETHONIUM; MAGNESIUM ION; MUSCARINIC M2 RECEPTOR; MUSCARINIC M5 RECEPTOR; OBIDOXIME; PYRIDINIUM DERIVATIVE; TACRINE; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CHEMICAL STRUCTURE; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RADIOASSAY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; DIMERIZATION; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PYRIDINIUM COMPOUNDS; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M5; RECOMBINANT FUSION PROTEINS; SWINE; TACRINE;

EID: 27844578733     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.017707     Document Type: Article

References (41)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Baldwin JM, Schertler GFX, and Unger VM (1997) An alpha carbon template for the transmembrane helices of the rhodopsin family of G-protein-coupled receptors. J Mol Biol 272:144-164.
3. Birdsall NJM and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5:523-543.
4. Böhm HJ (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput-Aided Mol Des 8:243-246.
5. Bonner TI, Buckley NJ, Young AC, and Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science (Wash DC) 237:527-532.
6. Buller S, Zlotos DP, Mohr K, and Ellis J (2002) Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol Pharmacol 61:160-168.
7. 2 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 357:363-370.
8. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
9. Eglen RM, Michel AD, Cornett CM, Kunysz EA, and Whiting RL (1989) The interaction of hexamethonium with muscarinic receptor subtypes in vitro. Br J Pharmacol 98:499-506.
10. Ellis J (1997) Allosteric binding sites on muscarinic receptors. Drug Dev Res 40:193-204.
11. Ellis J, Huyler J, and Brann M (1991) Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42:1927-1932.
12. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
13. Ellis J and Seidenberg M (2000) Interactions of alcuronium, TMB-8 and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol Pharmacol 58:1451-1460.
14. Flynn DD and Mash DC (1989) Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroamino-acridine. J Pharmacol Exp Ther 250:573-581.
15. Gharagozloo P, Lazareno S, Miyauchi M, Popham A, and Birdsall NJM (2002) Substituted pentacyclic carbazolones as novel muscarinic allosteric agents: synthesis and structure-affinity and cooperativity relationships. J Med Chem 45:1259-1274.
16. Hu MK, Wu LJ, Hsiao G, and Yen MH (2002) Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J Med Chem 45:2277-2282.
17. Jakubík J, Krejcí A, and Doležal V (2005) Asparagine, valine and threonine in the third extracellular loop of muscarinic receptor have essential role in the positive cooperativity of strychnine-like allosteric modulators. J Pharmacol Exp Ther 313:686-696.
18. 2 muscarinic acetylcholine receptor. J Comput-Aided Mol Des 16:795-801.
19. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation (1996) Trends Pharmacol Sci 17:280-283.
20. Kramer B, Rarey M, and Lengauer T (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37:228-241.
21. 2 receptors. Eur J Pharmacol 316:27-32.
22. Lanzafame A, Christopoulos A, and Mitchelson F (1997) Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors. J Pharmacol Exp Ther 282:278-285.
23. Lazareno S and Birdsall NJM (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109:1110-1119.
24. Lazareno S and Birdsall NJM (1995) Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G proteincoupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
25. 3H] scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol 58:194-207.
26. Lazareno S, Popham A, and Birdsall NJM (2002) Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 62:1492-1505.
27. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
28. Mohr M, Heller E, Ataie A, Mohr K, and Holzgrabe U (2004) Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84. J Med Chem 47:3324-3327.
29. 2 muscarinic allosteric modulators. Recept Channels 9:229-240.
30. 2 acetylcholine receptors: search for the minimum essential distances between the pharmacophoric elements. J Med Chem 42:849-858.
31. Palczewski K, Kumaska T, Hori T, Behnke CS, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G-protein-coupled receptor. Science (Wash DC) 289:739-745.
32. Pang YP, Quiram P, Jelacic T, Hong F, and Brimijoin S (1996) Highly potent, selective and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem 271:23646-23649.
33. 1 muscarinic receptors. Mol Pharmacol 35:652-660.
34. Rarey M, Kramer B, and Lengauer T (1997) Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J Comput-Aided Mol Des 11:369-384.
35. 2 receptors as deduced from buffer-dependent potency shifts. Naunyn-Schmiedeberg's Arch Pharmacol 362:512-519.
36. Tränkle C, Kostenis E, Burgmer U, and Mohr K (1996) Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 279:926-933.
37. 2 receptors. Mol Pharmacol 54:139-145.
38. 2 receptors. Mol Pharmacol 51:674-682.
39. 2 receptors. Mol Pharmacol 64:180-190.
40. 5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 64:21-31.
41. Wess J, Gdula D, and Brann MR (1992) Structural basis of the subtype selectivity of muscarinic antagonists: a study with chimeric m2/m5 muscarinic receptors. Mol Pharmacol 41:369-374.